Touchlight’s cell-free DNA platform offers a fundamentally different approach to DNA manufacturing—enabling the rapid, scalable, and high-quality production of enzymatically produced DNA for advanced therapies. At the core of this…
Touchlight’s Chief Scientific Officer, Dr. Jill Makin, discusses how the rapid evolution of advanced therapeutics is reshaping the industry, and why cell‑free DNA is has emerged as a foundational technology…
Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
In gene therapy manufacturing, viral vectors have long been the primary method for gene modification. However, recent innovations, combined with the evolving demands of the genetic medicines market, are driving…
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Why Cell-Free DNA Is Replacing Plasmids in Next-Gen Genetic Medicine In the fast-moving world of genetic medicine, cell-free DNA production has the potential to significantly advance the industry by making…
This white paper explores how Touchlight is redefining DNA payload design for next-generation gene editing and non-viral gene therapy. It introduces innovative circular DNA architectures such as mbDNA, sscDNA, hsscDNA,…
How to Scale DNA Production Effectively to Meet the Needs of Genetic Medicines DNA is the blueprint of life, carrying the molecular instructions that tell every cell how to…